Portfolio company Insilico Medicine listed on Hong Kong Stock Exchange, raising HKD 2.277 billion.
Insilico Medicine is a globally leading end-to-end generative AI-driven biotech company focused on accelerating drug discovery and development through its proprietary Pharma
Insilico Medicine is a globally leading end-to-end generative AI-driven biotech company focused on accelerating drug discovery and development through its proprietary Pharma.AI platform, which integrates biology, chemistry, and clinical development.